SANUWAVE Announces Q2 2023 Financial Results

EDEN PRAIRIE, MN – (NewMediaWire) – August 11, 2023 – SANUWAVE Health, Inc. (the “Company” or “SANUWAVE”) (OTCQB: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced its 2nd quarter 2023 results.

For the three months ended June 30, 2023:

  • Revenue for the three months ended June 30, 2023 totaled $4.7 million, an increase of 20%, as compared to $3.9 million for the same period of 2022. This growth falls within the previously provided guidance range of 15-25% for Q2 2023. Revenue for the six months ended June 30, 2023 totaled $8.5 million, an increase of 19%, as compared to $7.1 million for the same period of 2022.
  • 49 UltraMist® systems were sold in Q2 2023, up from 28 in Q1 of this year.
  • UltraMist® consumables revenue increased 25% to $2.8 million, versus $2.2 million for the same quarter last year on a 14% increase in treatments.  Revenue growth outpaced treatments due to higher average sale prices.
  • UltraMist® consumables revenue was 59% of overall revenue for Q2, up from 56% in the prior year period. This was primarily driven by a larger installed base, improved pricing, and higher usage rates.
  • Gross margin as a percentage of revenue increased to 74% for the three months ended June 30, 2023, vs 72% for the same period last year, primarily driven by stronger pricing initiatives.
  • For the three months ended June 30, 2023, operating income totaled $0.9 million, which is an improvement of $4.0 million compared to the same period in 2022.  This number benefited from a $1.25 million one-time reversal of accrued expenses and was partially offset by a $224 thousand non-cash stock compensation issuance.
  • Net loss for the three months ended June 30, 2023 was $7.3 million, compared to a net income of $1.6 million for the same period in 2022. The increase in net loss for the three months ended June 30, 2023 was primarily due to continued non-cash losses on the fair value of derivative liabilities.
  • The Company anticipates third quarter 2023 revenue growth will fall within a range of 15-25% as compared to the third quarter of 2022.



Recent Highlights from Q2 2023:

  • Appointment of Morgan Frank as Chief Executive Officer in May.
  • Appointment of Andrew Walko as President and to head manufacturing in July.
  • Signing of Distribution Agreement with Pacific Medical, Inc. bringing its sales force of over 215 representatives covering 7 western states to the UltraMist line of directed energy wound care products.
  • In July 2023, the Company issued Asset-Backed Secured Promissory Notes for which it received total proceeds of approximately $3.0 million.
  • SANUWAVE showcased its innovative non-invasive, regenerative medicine solutions for the treatment of chronic wounds at the Leaders in Wound Healing Conference in New Orleans, Louisiana, the Symposium on Advanced Wound Care Spring in National Harbor, Maryland, and the EWMA 2023 Symposium in Milan, Italy.
  • Leading plastic surgeon, Dr. Johnson presented on UltraMist at the Serena Foundation Leadership in Wound Conference.


“We are pleased to have generated significant revenue growth in Q2 despite ongoing capacity constraints,” said CEO Morgan Frank. “It has been a challenging time at SANUWAVE, but as these results are beginning to show, our drive toward cost cutting, process optimization, and margin expansion is beginning to gain traction as we move toward our near-term goals of growth acceleration and operating profitability.  In the coming quarters, we aim to continue and build upon this trend as we break the production and supply chain logjams that have prevented us from realizing the potential of the UltraMist system.”




The Company continued to have constrained inventory supply during Q2 2023 and anticipates this will improve in Q3, but remain a significant factor. The Company anticipates Q3 2023 revenue growth of approximately 15% to 25% year over year. SANUWAVE its constrained inventory supply will improve materially and enable an acceleration of revenue growth in Q4 2023.

As previously announced, a business update will occur via conference call on August 11, 2023.  Materials for the conference call at 8:30 a.m. EDT are included on the Company’s website,


Telephone access is available by dialing the following numbers:

Conference ID:  13740603

Telephone access to the call will be available by dialing the following numbers:

Participant Listening: 1-877-407-0784 or 1-201-689-8560


OR click the Call me™ link for instant telephone access to the event.


A replay will be made available through August 25, 2023:

Replay Dial-In: 1-844-512-2921 or 1-412-317-6671

Access ID: 13740603



SANUWAVE Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.

SANUWAVE’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. SANUWAVE applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations and constraints, and plans for future business development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with the regulatory approval and marketing of the Company’s product candidates and products, unproven pre-clinical and clinical development activities, regulatory oversight, the Company’s ability to manage its capital resource issues, competition, and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.



    (In thousands, except share data)  
          June 30, 2023   December 31, 2022  
Current Assets:            
  Cash       $ 332     $ 1,153    
  Restricted Cash       850          
  Accounts receivable, net of allowance of $1,214 and $1,037, respectively       2,818       4,029    
  Inventory         900       868    
  Prepaid expenses and other current assets       1,201       570    
Total Current Assets       6,101       6,620    
  Property, equipment and other, net       1,050       856    
  Intangible assets, net       4,786       5,137    
  Goodwill         7,260       7,260    
Total Non-current Assets       13,096       13,253    
Total Assets       $ 19,197     $ 19,873    
Current Liabilities:            
  Senior secured debt, in default     $ 16,123     $ 14,416    
  Convertible promissory notes payable       17,712       16,713    
  Convertible promissory notes payable, related parties       8,346       7,409    
  Bridge notes advance       1,476          
  Accounts payable       4,859       4,400    
  Accrued expenses       6,351       8,512    
  Factoring liabilities       1,213       2,130    
  Warrant liability       14,410       1,416    
  Accrued interest       6,174       4,052    
  Accrued interest, related parties       1,438       788    
  Current portion of contract liabilities       67       60    
  Other         1,108       291    
Total Current Liabilities       79,277       60,187    
Non-current Liabilities            
  Lease liabilities       515       438    
  Contract liabilities       215       230    
  Deferred tax liability       28       28    
Total Non-currrent Liabilities       758       696    
Total Liabilities     $ 80,035     $ 60,883    
Commitments and Contingencies (Footnote 13)            
Preferred Stock, par value $0.001, 5,000,000 shares authorized;            
  6,175 shares Series A, 293 shares Series B, 90 shares Series C and 8 shares Series D       $     $    
  no shares issued and outstanding at June 30, 2023 and December 31, 2022          
Common Stock, par value $0.001, 2,500,000,000 shares authorized; 561,637,651 and 548,737,651      
  issued and outstanding at June 30, 2023 December 31, 2022, respectively     562       549    
Additional paid-in capital       153,264       152,750    
Accumulated deficit       (214,584 )     (194,242 )  
Accumulated other comprehensive loss       (80 )     (67 )  
Total Stockholders’ Deficit       (60,838 )     (41,010 )  
Total Liabilities and Stockholders’ Deficit     $ 19,197     $ 19,873    
The accompanying notes to condensed consolidated financial statement are an integral part of these financial statements.  

Source link

Show More

Related Articles

Trending Tickers

Back to top button